55490-37-4

Usage

Molecular structure

1H-Pyrrole-2-propanoic acid, ethyl ester is a chemical compound composed of a pyrrole ring, a propanoic acid chain, and an ethyl ester group.

Derivation

It is derived from the combination of 1H-pyrrole, propanoic acid, and ethyl ester.

Usage

It is commonly used as an intermediate in the preparation of various pharmaceuticals and organic compounds, as well as in the synthesis of different types of polymers and materials.

Biological and pharmacological activities

It has been found to exhibit potential biological and pharmacological activities, making it a subject of interest in the field of medicinal chemistry and drug discovery.

Versatility

1H-Pyrrole-2-propanoic acid, ethyl ester is a versatile chemical that finds applications in various industries and research fields.

Upstream product

• 90610-08-5 3-pyrrol-2-yl-acrylic acid ethyl ester 
• 1071-46-1 hydrogen ethyl malonate 
• 1003-29-8 2-pyrrole aldehyde 
• 2433-65-0 3-(pyrrol-2-yl)acrylic acid ethyl ester 

Downstream Products

• 1403230-28-3 C₁₃H₁₄N₂O₅S 
• 1403230-14-7 C₁₃H₁₃IN₂O₄S 
• 1403230-27-2 C₁₅H₁₆N₂O₆S 
• 35419-02-4 4,5,6,7-tetrahydro-5-oxoindole 

Relevant academic research and scientific papers

QUINAZOLINE-2,4-DIONE DERIVATIVES AS PARP INHIBITORS

The present invention relates to compounds of formula (I) and compositions containing said compounds acting as PARP (Poly (ADP- ribose) polymerase) inhibitors. Moreover, the present invention provides processes for the preparation of the disclosed compounds, as well as methods of using them, for instance as a medicine, in particular for the treatment of cell proliferative disorders, such as cancer.

Virtual Screening Identifies Irreversible FMS-like Tyrosine Kinase 3 Inhibitors with Activity toward Resistance-Conferring Mutations

The use of covalent irreversible binding inhibitors is an established concept for drug development. Usually, the discovery of new irreversible kinase inhibitors occurs serendipitously, showing that efficient rational approaches for the rapid discovery of new drugs are needed. Herein, we report a virtual screening strategy that led to the discovery of irreversible inhibitors of FMS-like tyrosine kinase 3 (FLT3) involved in the pathogenesis of acute myeloid leukemia. A virtual screening library was designed to target the highly conserved Cys828 residue preceding the DFG motif by modification of reported reversible inhibitors with chemically reactive groups. Prospective covalent docking allowed the identification of two lead series, resulting in a massive increase in inhibition of kinase activity and cell viability by irreversible inhibitors compared to the corresponding reversible scaffolds. Lead compound 4b (BSc5371) displays superior cytotoxicity in FLT3-dependent cell lines to compounds in recent clinical trials and overcomes drug-resistant mutations.

BACKGROUND-FREE FLUORESCENT PROBES FOR LIVE CELL IMAGING

BODIPY (boron-dipyrromethene) containing fluorescent compounds for use in live cell intracellular imaging are described. Methods of producing the compounds, methods of labeling tagged organelles, and methods of live cell intracellular imaging using the compounds/probes are described herein.

Concise [4+3] cycloaddition reaction of pyrroles leading to tropinone derivatives

A concise [4+3] cycloaddition reaction of pyrroles with 2-(silyloxy)allyl cations has been developed. The oxyallyl cations stabilized with a methylthio group or geminal methyl groups were generated from the corresponding allylic alcohols under the influence of a Br?nsted acid (Tf2NH), respectively. The use of N-nosyl-protected pyrroles as the four-carbon unit was found to give tropinone derivatives in high yield.

Synthesis of 3′-BODIPY-labeled active esters of nucleotides and a chemical primer extension assay on beads

A solution-phase synthesis of active esters of 3′-fluoropho:relabeled deoxynucleoside 5′-monophosphates was developed for thymine and cytosine as nucleobases by using two different: BODIPY dyes. Starting from the respective 2′-amino2′,3′-dideoxynucleoside

BIOACTIVE COMPOUNDS FOR TREATMENT OF CANCER AND NEURODEGENERATIVE DISEASES

The invention provides bioactive compounds for the treatment of various malconditions such as cancer and neurodegenerative diseases including Alzheimer's disease. The chemical compounds as disclosed herein are found to show bioactivity in bioassays related to these conditions. Pharmaceutical compositions, combinations and methods of synthesis are provided, as are methods of using the compound, compositions and combinations in the treatment of the diseases.

Rhodium(II) catalyzed intramolecular insertion of carbenoids derived from 2-pyrrolyl and 3-indolyl α-diazo-β-ketoesters and α-diazoketones

α-Diazo-β-ketoesters and α-diazoketones derived from 2-pyrrolylacetic, 2-pyrrolylpropionic, 3-indolylacetic and 3-indolylpropionic acids afforded carbenoid derived cyclization products on treatment with catalytic rhodium(II) acetate.